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The study describes treatment for multidrug-resistant tuberculosis with individual drug
regimen adjusted according to the results of susceptibility tests. The patient tolerated all
drugs used very well. Although smear and culture negativity was reached, course of
disease was changed in the 7th year of the individual regimen, the disease progressed and
the patient died. Management of patients suffering from multidrug-resistant tuberculosis
is complicated and successful in 60–70% only. Therapy is performed either on the
recommendation for the resistant forms of tuberculosis or on the results of susceptibility
tests for antituberculous drugs of the second or third classes. In this case, even 7-year long
individual treatment regimen did not prevent patient from the exitus letalis.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Drug resistance has become a major problem in the
treatment of tuberculosis around the globe. The risk factors
for resistance include previous treatment and interruption
of therapy. Drug resistance has developed very often
because of the inappropriately or poorly implemented
primary programs of tuberculosis control.1 Resistant mu-
tants to any single antibiotic occur readily at random in
bacilli undergoing replication and may be selected for by not
using the adequate combination of drugs. Management ofElsevier Ltd. All rights reserved.
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.cz (V. Bartu).multidrug-resistant tuberculosis (MDR-TB) is usually very
complicated and treatment is successful in 60–70% of cases
only.2
The study documents that even 7-year long uninterrupted
individual treatment based on repeated susceptibility tests
did not prevent patient from the exitus letalis.Case report
On 1999, a 43-year-old white-male, smoker presented with
elevated temperature and cough. Epilepsy, liver disease,
chronic obstructive pulmonary disease (COPD) and no
evidence of drug use were mentioned in his anamnesis.
A negative result of HIV status was found on testing.
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Figure 1 Posteroanterior chest radiograph obtained 2 weeks
before patient’s death shows bilateral extensive tuberculous
inﬁltrations with cavities.
Unfavourable course of multidrug-resistant tuberculosis 151A chest X-ray showed inﬁltration on the left inferior lobe.
Patient was cured 6 months according to category III as
recommended by World Health Organization (WHO) in
Guidelines for national programmes in second edition 1997
for new smear-negative pulmonary tuberculosis.3 Patient
received directly observed therapy with a regimen of
isoniazid, rifampicin and pyrazinamid in the initial phase.
For continuation phase, isoniazid and rifampicin were used
for 4 months also under direct observation with good
patient’s compliance. The sputum was smear and culture
negative during the whole treatment period.
New pathological ﬁndings in the right middle and lower
zone and left superior lobe were detected on regular control
after 6 months of treatment on 2000. Sputum was culture
positive for Mycobacterium tuberculosis (M.TB) and there-
fore the regimen was changed to unapplied drugs strepto-
mycin, ethambutol, ethionamid and taroﬂoxacin, and
sputum sample was sent to the National Reference
Laboratory for drug sensitivity testing. The method of
minimal inhibitory concentration proved the presence of
multidrug-resistant M.TB with resistance to rifampicin
and isoniazid. The regimen was adjusted to a combination
of amikacin, ethambutol, oﬂoxacin, ethionamid and pyr-
azinamid according to the recommendation of WHO from
year 1997 as acceptable ‘‘third line’’ regimen for the
treatment of MDR-TB. Amikacin was applied for 3 months
without any adverse events and without elevation of
creatinine values. The 3-month duration of daily therapy
of aminoglycoside was recommended by WHO from year
1997. The patient was in a good clinical status for the
following 6 months. Bacteriological investigations of sputum
were repeated and positive culture ﬁndings were conﬁrmed
during second and third year of treatment without
any signiﬁcant changes on the chest X-ray. Because of
the unfavourable bacteriological results, susceptibility
tests were repeated in 2002 and conﬁrmed resistance to
ethambutol.
Therapy was adjusted again and combination of oﬂoxacin,
ethionamid, pyrazinamid, capreomycin was extended to
sensitive drug cycloserin to ensure the favourable course
and outcome of the therapy. The combination of all drugs
was tolerated very well. Patients suffered from COPD and he
was placed on bronchodilators. No interaction with anti-
tuberculous drugs was observed. Capreomycin was applied
for 3 months only and therapy continued on regimen with
remaining four drugs. Although patient was treated by
combination of four sensitive drugs, the sputum started to
be smear and culture positive intermittently in 2003–2005.
On the chest X-ray bilateral inﬁltrations proved partial
regression. The application of the regimen continued during
2006 and patient remained in the same clinical status.
Sputum samples were examined weekly and they started to
be smear and culture negative. Despite that the favourable
bacteriological ﬁndings, the progression of inﬁltration on
the chest X-ray was detected in 2006. During next several
months the sputum samples and the clinical status of the
patient changed to worse.
He was tired, grew slim and was suffering from cough,
sweating, temperature and dyspnoea. The evidence of
inﬂammation and malnutrition increased and the chest
X-ray proved bilateral progressions of inﬁltrates and cavities
(Figure 1). Patient died due to the cardio respiratory failureafter 7 years of uninterrupted individualized treatment
given under direct observation.Discussion
The antimicrobial resistance is the threat for global public
health that demands the international attention.4 The main
approaches to the identiﬁcation of MRD-TB are the estab-
lishment of history of previous TB treatment and drug
susceptibility tests.5,6 Susceptibility tests for the ﬁrst- and
second-line drugs should always be performed for patients
with possible treatment failure or relapse. This recommen-
dation was followed also in this study case and susceptibility
test conﬁrmed multidrug resistance.
The monitoring of treatment efﬁciency is based on three
indicators: (1) clinical response, (2) chest radiographs and
(3) repeated sputum microscopy, culture and susceptibility
testing.7 Patient should be evaluated for symptoms and signs
of tuberculosis, adherence to treatment and adverse
reactions to the medications at least every month, sputum
specimens for M.TB smear and culture should also be
obtained monthly. If cultures remain positive after 2–4
months of treatment, susceptibility tests should be repeated
as it was done in this case. To ﬁnish the therapy successfully,
the regimen should always continue for 18–24 months after
bacteriological smear and culture sputum conversion.5,8
This, however, was not the case of the patient studied as the
tests turned positive and the clinical status worsens.
Management of MDR-TB is quite complicated, but general
guidelines were presented by Iseman and WHO.8,9 It is based
on the establishment of suitable individualized drug treat-
ment. The individualized treatment regimen is based on the
results of drug susceptibility tests of the speciﬁc strain,
patient’s treatment history and changes of the infecting
strain during the treatment period. The therapy should be
started in the hospital to permit observation of intolerance
ARTICLE IN PRESS
V. Bartu, E. Kopecka152and to allow a change of a regimen. The recommended
number of drugs not previously used for individual regimens
varies in the literature. Three or four drugs are usually
recommended.5,8 The use of the second-line antitubercu-
lous drugs, which are more expensive, more toxic and less
effective than the ﬁrst-line drug, is required.6,9 The therapy
is adjusted and switched according to the laboratory results
of resistance pattern, clinical deterioration and bacteriolo-
gical ﬁndings of sputum samples.
Drug resistance is strongly associated with previous
treatment and can develop in some cases in less than 1
month.7 The probability of development of resistance to a
drug increases with the length of time it has been
administered. Evidence of bacteriological treatment failure
during a period of regular drug administration is highly
suggestive of drug resistance. In this patient the conversion
from drug susceptible tuberculosis case to an MDR-TB case is
supposed. Second-line antibiotics have lower bactericidal
activities compared with ﬁrst-line ones and therefore the
selection due to a reduced antibiotic pressure is faster. It
could explain the changes of susceptibility patterns,
increasing drug resistance and the ﬁnal unfavourable
outcome seen in this patient.
Generally, the results of medical therapy of MDR-TB are
not satisfactory and about 40% of treatment failure patients
have poor prognosis. Favourable bacteriological response to
chemotherapy usually occurs within 4 months.10 In this case
studied the bacteriological conversion of sputum was found
much later. The patient studied did not fulﬁl the criteria for
surgery approach because of the bilateral pulmonary
ﬁndings and poor lung function tests parameters. The
surgery was not used in his therapy. Duration of the
treatment of MDR-TB up to 3 years is quite difﬁcult due to
side effects and often not very successful.2 However, if the
surgery is contraindicated, the drug treatment remains the
only possibility for the patient even the duration of therapy
has been longer than 3 years. In this case it was quite
difﬁcult to ﬁnish the therapy after 3 years because the
patient was in good clinical condition and there was a hope
for favourable outcome.
This study presents extremely prolonged course of MDR-
TB with 7-year period of directly observed individual
treatment regimen. This regimen included the use of severaldrugs that were changed according to the susceptibility
tests during the therapy period. Despite that the transient
improvement of the bacteriological samples was documen-
ted after 6 years of the therapy, the progression of the chest
X-ray, smear and culture positive ﬁndings and the worsening
of the clinical status were observed during the following
months.Conﬂict of interest statement
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